[{"id":"909b05f4-54e7-46d6-9858-219e4d8aa66a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04836663","created_at":"2021-04-08T12:52:19.761Z","updated_at":"2024-07-02T16:36:29.666Z","phase":"Phase 2","brief_title":"A Study of TQ-B3525 Tablets in Subjects With PIK3CA and/or PIK3R1/2 Gene-altered Recurrent/Metastatic Advanced Gynecologic Tumors","source_id_and_acronym":"NCT04836663","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" PIK3CA • PIK3R1","pipe":"","alterations":" ","tags":["PIK3CA • PIK3R1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TQ-B3525"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 04/23/2021","start_date":" 04/23/2021","primary_txt":" Primary completion: 09/30/2022","primary_completion_date":" 09/30/2022","study_txt":" Completion: 12/30/2022","study_completion_date":" 12/30/2022","last_update_posted":"2021-05-31"},{"id":"ea0c70bf-d79a-4a55-a1cf-881b61a43371","acronym":"TQBSP","url":"https://clinicaltrials.gov/study/NCT04690725","created_at":"2021-01-19T20:48:34.538Z","updated_at":"2024-07-02T16:36:36.671Z","phase":"Phase 1/2","brief_title":"TQB3525 for Advanced Bone Sarcomas With PI3KA Mutations or PTEN Loss","source_id_and_acronym":"NCT04690725 - TQBSP","lead_sponsor":"Peking University People's Hospital","biomarkers":" PTEN","pipe":" | ","alterations":" PTEN loss","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN loss"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TQ-B3525"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 10/01/2020","start_date":" 10/01/2020","primary_txt":" Primary completion: 01/01/2022","primary_completion_date":" 01/01/2022","study_txt":" Completion: 06/01/2022","study_completion_date":" 06/01/2022","last_update_posted":"2020-12-31"},{"id":"399d62ba-99dc-4de9-b47c-5226b04ae5a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04355520","created_at":"2021-01-18T21:03:55.223Z","updated_at":"2024-07-02T16:36:45.763Z","phase":"Phase 1/2","brief_title":"A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer","source_id_and_acronym":"NCT04355520","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" HER-2 • PIK3CA","pipe":" | ","alterations":" HR positive • HER-2 negative • PIK3CA mutation","tags":["HER-2 • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • TQ-B3525"],"overall_status":"Unknown status","enrollment":" Enrollment 42","initiation":"Initiation: 07/01/2020","start_date":" 07/01/2020","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 09/01/2021","study_completion_date":" 09/01/2021","last_update_posted":"2020-04-21"}]